ProCE Banner Activity

CodeBreaK 200 Phase III Trial: Sotorasib vs Docetaxel for Patients With Previously Treated Advanced NSCLC With KRAS G12C Mutation

Slideset Download
Conference Coverage
In CodeBreaK 200, sotorasib significantly increased progression-free survival and ORR vs docetaxel in patients with previously treated KRAS G12C–mutated advanced non-small-cell lung cancer.

Released: September 22, 2022

Expiration: September 21, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp